Clinical Trials · NCT01394952
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 9,901
- Start date
- Jul 2011
- Locations
- 300 sites, 25 countries
- Primary endpoint
- Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)